Mangoceuticals, Inc. MGRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -38.90% | -18.88% | -25.96% | -38.18% | -40.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -38.90% | -18.88% | -25.96% | -38.18% | -40.48% |
| Cost of Revenue | -28.63% | -8.83% | -12.84% | -41.20% | -44.50% |
| Gross Profit | -45.49% | -26.26% | -34.11% | -36.05% | -37.59% |
| SG&A Expenses | 3.33% | 87.16% | 108.21% | 108.10% | 36.51% |
| Depreciation & Amortization | 55.59% | 55.59% | 55.59% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.79% | 82.66% | 100.70% | 110.98% | 41.26% |
| Operating Income | -7.68% | -88.32% | -110.17% | -124.88% | -49.96% |
| Income Before Tax | -6.34% | -71.81% | -137.09% | -112.54% | -55.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.34% | -71.81% | -137.09% | -112.54% | -55.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -12.50% | -63.64% | -50.00% | 12.50% | 166.67% |
| Net Income | -6.34% | -71.83% | -137.11% | -112.55% | -55.63% |
| EBIT | -7.68% | -88.32% | -110.17% | -124.88% | -49.96% |
| EBITDA | -18.09% | -95.83% | -108.48% | -101.34% | -26.51% |
| EPS Basic | 65.82% | 61.16% | 45.55% | 47.78% | 45.31% |
| Normalized Basic EPS | 68.35% | 63.88% | 49.04% | 48.73% | 49.16% |
| EPS Diluted | 65.82% | 61.16% | 45.55% | 47.78% | 45.31% |
| Normalized Diluted EPS | 68.35% | 63.88% | 49.04% | 48.73% | 49.16% |
| Average Basic Shares Outstanding | 208.75% | 375.75% | 406.85% | 332.52% | 237.73% |
| Average Diluted Shares Outstanding | 208.75% | 375.75% | 406.85% | 332.52% | 237.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |